FDA Orange Book · active-ingredient family
Olanzapine pamoate
Olanzapine pamoate: 1 brand, 0 generics; first approved Dec 11, 2009.
Brand only
Generic status & protection
No listed patents or exclusivity: brand product(s) only.
Brands (NDA)
1
Generics (ANDA)
0
Listed patents
0
Presentations
3
Brand (NDA) products
Originator applications
- CHEPLAPHARMNDA 02217320093 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 210MG BASE/VIAL SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR Rx — EQ 300MG BASE/VIAL SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR Rx — EQ 405MG BASE/VIAL SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR Rx —
Listed patents
Orange Book patent file
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
FDA approval span
First approval
16 yr 10 mo ago
Most recent approval
16 yr 10 mo ago
All 1 application were approved in 2009.
Brand (NDA) 1100%
Generic (ANDA) 00%
Olanzapine pamoate: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
